Inovio Pharmaceuticals

Inovio's chairman elected fellow by AAAS

Wednesday, March 14, 2012 09:16 AM

Inovio Pharmaceuticals’ advisory board chairman David B. Weiner, PhD, has been elected a fellow in the nonprofit American Association for the Advancement of Science (AAAS).

More... »

Inovio vaccine shows long-term durability

Wednesday, July 20, 2011 11:04 AM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, has reported long-term durability of T cell immune responses of up to over two years (at the latest time measured) in seven of eight evaluated patients following a fourth vaccination of VGX-3100, its investigational SynConR DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV) that is delivered using intramuscular electroporation.

More... »

Inovio releases phase I flu vaccine results

Friday, July 15, 2011 10:27 AM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, announced that significant T cell and antibody responses were generated in its phase I clinical study of VGX-3400X, a SynCon DNA vaccine for the prevention of avian H5N1 influenza delivered using intramuscular (IM) electroporation.

More... »

Inovio Pharmaceuticals names Dr. Avtar Dhillion chairman

Wednesday, July 6, 2011 10:29 AM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, has named Dr. Avtar Dhillon non-executive chairman of the board of directors.

More... »

Inovio reports positive responses from cervical dysplasia vaccine

Monday, May 9, 2011 12:48 PM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus (HPV).

More... »

Inovio Pharmaceuticals initiates phase II trial of DNA vaccine

Thursday, March 17, 2011 12:43 PM

Inovio Pharmaceuticals, a developer of therapeutic and preventive vaccines against cancers and infectious diseases, said its partner ChronTech Pharma  (formerly Tripep ), has initiated a phase IIb clinical study of its ChronVac-C DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary electroporation DNA vaccine delivery technology, in combination with standard of care.

More... »